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ABSTRACT
Hepatocellular adenomas (HCAs) are benign tumors, of which the
most serious complications are hemorrhage and malignant
transformation to hepatocellular carcinoma (HCC). Among the
various subtypes of HCA, the β-catenin-activated subtype (bHCA) is
associated with greatest risk of malignant transformation. Magnetic
resonance imaging (MRI) is an important tool to differentiate benign
and malignant hepatic lesions, and preclinical experimental
approaches may help to develop a method to identify MRI features
associated with bHCA. HCAs are associated with various pathologies,
including glycogen storage disease 1a (GSD1a). Here, we utilized a
mouse model for GSD1a that develops HCA and HCC, and analyzed
the mice in order to distinguish low-risk from high-risk tumors. Animals
were scanned byMRI using a hepato-specific contrast agent. Themice
were sacrificed after MRI and their lesions were classified using
immunohistochemistry. We observed that 45% of the animals
developed focal lesions, and MRI identified four different
patterns after contrast administration: isointense, hyperintense and
hypointense lesions, and lesions with peripheral contrast
enhancement. After contrast administration, only bHCA and HCC
were hypointense in T1-weighted imaging and mildly hyperintense in
T2-weighted imaging. Thus, high-risk adenomas display MRI features
clearly distinguishable from those exhibited by low-risk adenomas,
indicating that MRI is a reliable method for early diagnosis and
classification of HCA, necessary for correct patient management.
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INTRODUCTION
Hepatocellular adenomas (HCAs) are benign tumors that constitute
2% of all liver tumors, and their most important complications are
hemorrhage and malignant transformation to hepatocellular
carcinoma (HCC) (Stoot et al., 2010).
HCAs have been classified into four subgroups on the basis of their
pathogenesis: HHCA, containing bi-allelic inactivating mutations of
hepatocyte nuclear factor 1 alpha; bHCA, characterized by activating
mutations of the gene encoding β-catenin and associated with
greater risk of malignant transformation than the other subtypes;
inflammatory HCA (IHCA), characterized by inflammatory
infiltrates and high expression of C-reactive protein (CRP) and
serum amyloid A2 (SAA2) (∼10% of IHCAs are also β-catenin
mutated); and unclassified HCA (UHCA), accounting for less than
10% of the cases (Bioulac-Sage et al., 2010, 2007; Zucman-Rossi
et al., 2006; Nault et al., 2017).
HCAs are frequently associated with glycogen storage disease
(GSD) 1a (Franco et al., 2005; Labrune et al., 1997; Reddy et al.,
2007). GSD1a is an autosomal recessive disorder caused by
mutations in the catalytic subunit of glucose-6-phosphatase-alpha
(G6Pase-α), a key enzyme in glucose metabolism (Lei et al., 1993).
The chronic dysmetabolism affects the functions of liver and
kidney, resulting in a progressive worsening of the clinical
parameters and development of hepatic adenomas that may
undergo malignant transformation. In a European cohort study,
HCAs were observed in 80% of the patients with GSD1a above the
age of 30 years. Furthermore, 10% of GSD patients developed HCC
(Lee, 2002).
Fifty-two percent of GSD adenomas can be classified as IHCA,
28% as bHCA and the remaining 20% as UHCA (Calderaro et al.,
2013). The elevated percentage of adenomas with β-catenin-
activating mutations may explain the risk of malignant
transformation of HCA in HCC in GSD1a patients.
Magnetic resonance imaging (MRI) represents an important tool
to differentiate benign and malignant hepatic lesions, particularly
because of the possibility to combine information obtained with
different sequences, such as T1- and T2-weighted imaging (WI),
diffusion WI (DWI) and post-contrast T1-WI, using hepatobiliary
gadolinium contrast agents such as gadobenate dimeglumine
(Gd-BOPTA) and gadoxetic acid (Gd-EOB) (Oliva and Saini,
2004).
Correlation between MRI and the genotype-phenotype
classification of HCAs has been attempted (Laumonier et al.,
2008; van Aalten et al., 2011; Yoneda et al., 2012). Characteristic
MRI profiles for HHCA and IHCA have been identified, but no
specific MRI profile can be proposed for the identification of
high-risk bHCA cases. In consideration of this, the subtyping and
classification of liver adenomas for HCC risk prediction in humans
still requires invasive procedures, i.e. biopsies.
A preclinical experimental approach may help to develop a
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Fig. 1. Immunoclassification of adenomas in LS-G6pc−/−mice. LS-G6pc−/−mice livers were fixed with 10% formalin and paraffin embedded. Serial sections
were stainedwithHematoxylin andEosin (H&E) or treatedwith anti-serumamyloid (SAA) or anti-glutamine synthetase (GS) antibody. (A) Histological features and
immunohistochemistry analysis of liver adenomas in LS-G6pc−/−mice. H&E-stained section of an IHCA (a). An IHCAnodule showsdiffuse positivity for SAAwithin
the lesion, while the surrounding parenchyma is negative except for perivascular amyloid deposition (b). The same nodule shows negativity for GS antibody, while
the surrounding non-lesional parenchyma shows normal GS staining in perivascular hepatocytes (asterisk) (c). The images shown are representative of 17 IHCA
lesions examined. H&E-stained section of a bHCA (d). A bHCA nodule is negative for SAA (e) but shows strong positivity for GSwithin the lesion (double asterisk),
while the surrounding non-lesional parenchyma shows normal zonation of expression in perivascular hepatocytes (asterisk) (f ). The images shown are
representative of eight bHCA lesions examined. H&E-stained section of anUHCA (g). AnUHCAnodule is negative for both SAA (h) andGS (i). The images shown
are representative of 12 UHCA lesions examined. (a-c) 10× magnification; (d-i) 4× magnification. (B) Histological features and immunoexpression of GS in a
hepatocellular carcinoma (diamonds) (a,b,c) and in a normal control murine liver (d,e,f ). (a) H&E-stained section of a nodule showing atypia (diamond); a contour
(dotted line) has been drawn between the HCC (left) and normal surrounding tissue (right). (b) Strong and diffuse positivity to GS within the lesion (diamond).
(c) An HCC section with Gomori staining for reticulin framework, showing loss of reticulin framework typical of malignancy (diamond). Reticulin is preserved
in the surrounding parenchyma; a contour (dotted line) has been drawn between the HCC (left) and normal surrounding tissue (right). The images shown are
representative of threeHCCs examined. (d) H&E-stained section of normal liver. (e) Strong positivity to GS is observed in the perivascular hepatocytes of a normal
liver control. (f ) Gomori staining of normal liver showing preserved reticulin trabecular framework and perivascular collagen. (a-f ) 20× magnification.
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bHCA subtype. In this respect, we have generated and characterized
a mouse model for GSD1a in which the deletion of G6pc, the gene
encoding G6Pase-α, occurs only in the liver. These mice
(LS-G6pc−/−) mimic all the steps of the liver disease progression,
including the development of HCA and transformation to HCC,
providing a link between G6Pase-α deficiency and neoplastic liver
progression (Resaz et al., 2014).
In this study, we assessed the detection level and quantified
the longitudinal evolution of liver lesions in LS-G6pc−/− mice
in order to characterize HCAs and HCC using a dedicated protocol,
optimized for high magnetic field strength, and a hepato-specific
contrast agent. We show that bHCA displays MRI features
distinguishable from those exhibited by IHCA or UHCA,
indicating that MRI is a reliable method to identify high-risk HCA.
RESULTS
Characterization of hepatic focal lesions in LS-G6pc−/− mice
LS-G6pc−/− mice livers were histologically examined. Liver
parenchyma showed the classical histological features of GSD1a
(Resaz et al., 2014; Chou et al., 2010). All HCAs were histologically
examined and immunostained for pathological classification.
Histological analysis of HCA of LS-G6pc−/− mice showed that
they were unencapsulated nodules composed of hepatocytes with
no or little atypia and with no or few intralesional portal tracts
(Fig. 1A,a,d,g).
Anti-glutamine synthetase (GS) antibody, to identify bHCA
(high-risk adenoma), and anti-serum amyloid A (SAA) antibody, to
identify IHCA, was used. For GS, only a strong and diffuse
cytoplasmic staining was considered positive, and staining intensity
Table 1. Number and type of lesions in LS-G6pc−/− mice
Nodules T1 signal intensity T2 signal intensity
Mice with nodules Total number of nodules Histology SI lesion SI liver RelSI SI lesion SI liver SI lesion/SI liver
1 1 UHCA 360# 1672 0.22
2 1 UHCA 899# 2048 0.40
3 4 IHCA 3050 2414 1.26
IHCA 1750# 2550 0.69
IHCA 1872# 2664 0.70
bHCA 499 2577 0.19 420 129 3.26
4 2 UHCA 759 1548 0.49
UHCA 2450 1500 1.63
5 1 IHCA 718# 1544 0.47
6 4 IHCA 3021 2213 1.37
IHCA 3143 2167 1.45
bHCA 1328 2134 0.62 64 47 1.36
HCC 1337 2247 0.60 51 35 1.46
7 2 IHCA 893# 1671 0.53
UHCA 1142 1642 0.70
8 2 IHCA 3250 2478 1.31
bHCA 750 2550 0.29 390 135 2.89
9 1 HCC 519 2406 0.22 326 119 2.74
10 1 UHCA 1237 2189 0.57
11 3 IHCA 2010 1367 1.47
UHCA 771 1367 0.56
UHCA 622 1367 0.46
12 2 IHCA 1268# 1495 0.85
UHCA 608 1288 0.47
13 3 IHCA 1642 1411 1.16
IHCA 1298 1091 1.19
bHCA 634 1251 0.51 298 168 1.77
14 3 IHCA 1847 783 2.36
bHCA 381 991 0.38 333 138 2.41
HCC 766 828 0.93 296 138 2.14
15 5 IHCA 2155 967 2.23
IHCA* 2130 951 2.24
bHCA 547 1185 0.46 186 114 1.63
UHCA 821 1017 0.81
UHCA 810 1017 0.80
16 4 IHCA 1650 860 1.92
bHCA 586 835 0.70 166 112 1.48
UHCA 779 844 0.92
UHCA 753 817 0.92
17 1 IHCA 2450 1500 1.63
18 1 bHCA 573 1007 0.57 161 52 3.10
18 mice showed the presence of focal lesions by MRI analysis. Nodules were analyzed by immunohistochemistry. A total of 41 lesions were characterized;
18/41 tumors were classified as IHCA, 8/41 as bHCA, 12/41 as UHCA and 3/41 as HCC.
Quantitative intensity of lesions was expressed as relative signal intensity ratio (RelSI) for each lesion, calculated both on T1-WI after contrast administration and
on T2-WI. Lesion and liver signal intensity (SI) was measured using an operator-defined region of interest (ROI). After defining the ROIs, we calculated the RelSI
according to the formula: RelSI=SI lesion/SI liver.
*This lesion stained positive for both SAA and GS, and was therefore considered a high-risk IHCA.
#Lesions with peripheral rim of enhancement.
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was comparable to the staining in normal liver in the centrilobular,
perivenular hepatocytes. SAA marked IHCA hepatocytes with
granular cytoplasmic staining and amyloid deposits in vascular
and/or sinusoidal spaces. We previously reported that 90% of
LS-G6pc−/−mice develop amyloidosis by 12 months of age (Resaz
et al., 2014).
HNF1α-mutated HCAs have not been identified in GSD-related
HCAs (Calderaro et al., 2013). Therefore, silenced FABP1 was not
searched for in the LS-G6pc−/− mouse liver tumors.
Eighteen nodules stained positive for SAA and negative for GS,
and were identified as IHCA (Fig. 1A,b,c); eight nodules stained
negative for SAA and positive for GS, and were identified as
high-risk bHCA (Fig. 1A,e,f ); and 12 nodules were negative for
both SAA and GS, and were classified as UHCA (Fig. 1A,h,i).
Moreover, three lesions were well-differentiated HCCs (Fig. 1B,a),
characterized by positive staining for GS (Fig. 1B,b) and loss of
reticulin framework (Fig. 1B,c). These results, summarized in
Table 1, are in agreement with the molecular characterization of
HCA in patients with GSD1a (Calderaro et al., 2013).
Correlation between MRI signals and immunohistological
analysis in livers of LS-G6pc−/− mice
To characterize the hepatic lesions detected in LS-G6pc−/− mice
and correlate MRI features with the different adenoma subtypes,
40 animals aged 13-18 months were scanned by 3T clinical MRI
and checked for focal lesions in all sequences acquired. A total of
41 liver lesions were detected in 18 of the 40 animals analyzed, with
an incidence of 45%. Twenty-five mice were scanned once and
sacrificed immediately after MRI acquisition. The remaining
15 mice were monitored every 4 weeks for 3 months to evaluate
lesion growth and complication onset, such as rupture and bleeding
(see Table 2), as described below.
MRI identified four different patterns of contrast uptake after
contrast administration: isointense, very hyperintense, and very
hypointense lesions, and lesions with a peripheral contrast
enhancement. All typical IHCA lesions were isointense on
pre-contrast T1-WI and on T2-WI (Fig. 2A,C). On T1-WI after
contrast administration, 11/18 (61%) of the IHCA lesions showed a
very hyperintense signal compared to the surrounding liver (Fig. 2B),
while 6/18 (33%) showed a peripheral rim of contrast enhancement
and central hypointensity (Fig. 3D,E). We observed one case of
adenoma (1/18, 6%) featuring high expression of both SAA and GS
(data not shown). This lesion was isointense on pre-contrast T1-WI
(Fig. 2D) and, after contrast administration, was hyperintense and
characterized by the presence of a faint hypointense central scar
(Fig. 2E,E′). On T2-WI, the lesion was isointense, while the central
scar was mildly hyperintense (Fig. 2F,F′).
None of the bHCA lesions, featuring GS overexpression, showed
hyperintensity compared to the surrounding liver in the hepatocyte
phase or peripheral rim of contrast enhancement after contrast
sequences. We observed that 8/8 lesions (100%) were very
hypointense after contrast administration on T1-WI and mildly
hyperintense on T2-WI (Fig. 2G-I).
All well-differentiated HCCs (3/3) were mildly hyperintense on
T2-WI, isointense on T1-WI before contrast, and very hypointense
(2/3) (Fig. 2J-L) or mildly hypo/isointense (1/3) on T1-WI after
contrast administration (not shown).
UHCA showed all four different contrast enhancement patterns on
T1-WI after contrast: the majority (7/12) were very hypointense
lesions, 2/12 were isointense, 1/12 were very hyperintense and 2/12
werewith a peripheral ring of contrast enhancement. Fig. 2M-O show
representative images of a very hypointense UHCA lesion. All
UHCA lesions were isointense on T2-WI (Fig. 2O), unlike bHCA
and HCC lesions, which were mildly hyperintense (Fig. 2I,L).
These results, summarized in Table 3, indicate that our MRI
protocol can be used to identify HCA and to distinguish high-risk
from low-risk adenomas. MRI could therefore represent a less-
invasive tool for early diagnosis and classification of HCA
necessary for correct patient management.
Monitoring of hepatic lesions
In order to characterize the evolution and growth of the liver lesions in
LS-G6pc−/− mice, we performed periodic MRI on 15 LS-G6pc−/−
mice aged 13-15 months. The animals weremonitored every 4 weeks
for 3 months, and the tumor growth was analyzed by measuring
lesion diameter using the off-line workstation. Tumor measurement
was performed on the basis of T1-weighted contrast-enhanced scans.
Seven mice showed the presence of nodules.
Time-dependent monitoring demonstrated that hyperintense
lesions (n=4) on contrast-enhanced T1-WI, without evidence of
hyperintensity on T2-WI, had a slow growth rate. All these lesions
were identified by immunohistochemistry as IHCA. A representative
nodule is shown in Fig. 4.
At the first MRI evaluation, one of these mice showed two very
hypointense nodules on T1-WI after contrast administration
(Fig. 5A). Interestingly, these two lesions showed different
signals on T2-WI imaging: the smaller one was, at the first MRI
examination, isointense (Fig. 5B, arrow), while the bigger one was
mildly hyperintense (Fig. 5B, dashed line arrow).
After 1 month, one of the lesions had only slightly changed in size
(Fig. 5C, arrow) but had become mildly hyperintense on T2-WI
(Fig. 5D, arrow), while the other lesion had significantly increased in
size (Fig. 5C, dashed line arrow), remaining hyperintense on T2-WI
(Fig. 5D, dashed line arrow) with an internal cystic degeneration.
Table 2. Study protocol
Number of mice Age of mice at first MRI (months) Age of mice at last MRI (months) Number of MRI analyses performed Time of sacrifice
4 19 NA 1 Right after image acquisition
10 17 (7) and 18 (3) NA 1 Right after image acquisition
9 15 (4) and 16 (5) NA 1 Right after image acquisition
2 14 NA 1 Right after image acquisition
Total: 25
4 13 16 3 (every 4 weeks for 3 months) Right after last MRI analysis
6 14 17 3 (every 4 weeks for 3 months) Right after last MRI analysis
5 15 18 3 (every 4 weeks for 3 months) Right after last MRI analysis
Total: 15
25mice aged 13-18 months were analyzed by MRI and sacrificed after image acquisition. 15 mice aged 13-15 months were analyzed by MRI every 4 weeks for 3
consecutive months and then sacrificed for further analysis. NA, not applicable.
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Fig. 2. MRI of various subtypes of liver lesions in LS-G6pc−/− mice. LS-G6pc−/− mice were scanned by MRI and checked for focal lesions in all acquired
sequences. (A-C) A typical IHCA is isointense on T1-WI before contrast administration (c.a.) (A) and on T2-WI (C), while on T1-WI after c.a. it shows areas of
hyperintensity compared to the surrounding liver (B, arrow). The images shown are representative of 17 IHCA lesions examined. (D-F) The single atypical IHCA is
isointense on T1-WI before c.a. (D), hyperintense on T1-WI after c.a. (E, arrow) and isointense on T2-WI (F), and characterized by the presence of a faint
hypointense central scar (E’) that is mildly hyperintense on T2-WI (F, arrow and F′). (G-I). A bHCA lesion is isointense compared to the liver parenchyma on T1-WI
before c.a. (G), hypointense on contrast-enhanced T1-WI (H, arrow) and mildly hyperintense on T2-WI (I, arrow). The images shown are representative of eight
bHCA lesions examined. (J-L) The HCC shown is isointense on T1-WI acquired before c.a. (J, arrow), while it shows prominent hypointensity on T1-WI after c.a.
(K, arrow) and is slightly hyperintense on T2-WI (L, arrow). The images shown are representative of three HCCs examined. (M-O) A UHCA lesion is isointense on
T1-WI before c.a. (M) and hypointense on T1-WI after c.a. (N, arrow). The nodule is isointense compared to the liver parenchyma on T2-WI, different from bHCA
and HCC (O). The images shown are representative of 12 UHCAs examined.
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At the third MRI evaluation, the smaller lesion showed 50%
increase in size, suggesting a fast growth rate (Fig. 5E, arrow). Both
lesions remained mildly hyperintense on T2-WI (Fig. 5F) and were
classified by immunohistochemistry as UHCA.
These findings support the hypothesis that lesions hypointense
on hepatobiliary contrast phase (HBP) and mildly hyperintense on
T2-WI are rapidly growing tumors. This preliminary experiment
underlies the need for further studies to better understand the real
biological behavior of UHCA.
A third lesion, hyperintense on post-contrast T1-WI (Fig. 5E,
arrowhead) was visualized at this stage and characterized as
an IHCA.
DISCUSSION
Several animal models of liver disease have been developed and
extensively utilized in many preclinical medical research studies to
investigate disease onset and progression (Fausto and Campbell,
2010; Gabele et al., 2011; Jacobs et al., 2016; He et al., 2015; Yan
et al., 2011). Development of HCA in LS-G6pc−/− mice is the
consequence of a single gene mutation that inhibits G6Pase function
and leads to liver degeneration and tumorigenesis. Thus, LS-G6pc−/−
mice are of major interest because they mimic spontaneous HCA
formation with aging and evolution into HCC as in GSD1a patients.
To date there has been a lack of an appropriate in vivo detection
system that allows continuous monitoring of tumor onset and
progression. HCC high-risk patients are monitored through imaging
surveillance, and focal nodule characterization is performed with
multiphase contrast material-enhanced computed tomography (CT)
and/orMRI. Because of variability in lesion interpretation, the Liver
Imaging Reporting and Data System (LI-RADS) was created with
the aims of improving HCC diagnosis and therapeutic management
(Purysko et al., 2012).
Hepatobiliary contrast agents have significantly increased
diagnostic accuracy in the detection and characterization of focal
liver lesions and its role was recently recognized in the latest
version of CT/MRI LI-RADS criteria (v2017), which considers
HBP as an ancillary feature in lesion characterization i.e. HBP
hypointensity favoring malignancy in general and HBP isointensity
favoring benignity (Elsayes et al., 2017).
We set up a protocol to assess the detection level and quantify the
longitudinal evolution of liver lesions in LS-G6pc−/− mice using
non-contrast T1-WI/T2-WI and non-dynamic post-contrast
hepatobiliary imaging. We based our differential diagnosis on
features considered ancillary by LI-RADS, especially mild to
moderate T2 hyperintensity. The hepato-specific contrastographic
phase allows the differentiation of lesions on the basis of hepatocyte
Fig. 3. Different enhancement patterns of focal hepatic lesions. LS-G6pc−/− mice were scanned by MRI. (A-E) The four different patterns of contrast
uptake are shown: isointense (A); hyperintense (B); hypointense (C); hypointense lesions with peripheral rim of contrast enhancement from two different mice
(D,E). Lesions are indicated by arrows. The results shown are representative of 40 mice examined.
Table 3. MRI characteristics of the lesions in G6pc−/− liver
Subtype
T1-WI before c.a. T2-WI T1-WI after c.a.
Isointense
Hyperintense/




IHCAa SAA+/GS− 17/18 0/18 17/18 0/18 0/18 11/18 6/18 0/18
SAA+/GS+ 1/18 0/18 1/18 0/18 0/18 1/18 0/18 0/18
bHCAb GS+/SAA− 8/8 0/8 0/8 8/8 0/8 0/8 0/8 8/8
HCCc GS+ 3/3 0/3 0/3 3/3 1/3 0/3 0/3 2/3
UHCAd SAA−/GS− 12/12 0/12 12/12 0/12 2/12 1/12 2/12 7/12
Animals were scanned by MRI and checked for focal lesions. Nodules were characterized by immunohistochemistry.
aIHCA lesions were isointense on T1-WI before contrast administration (c.a.) and on T2-WI. On T1-WI after c.a., 12/18 lesions were hyperintense and 6/18 lesions
were hypointense with peripheral rim of contrast enhancement.
bbHCA lesions were isointense on T1-WI before c.a., hyperintense on T2-WI and hypointense on T1-WI after c.a.
cHCC lesionswere isointense on T1-WI before contrast enhancement and hyperintense on T2-WI. On T1-WI after c.a., 2/3 HCC lesionswere hypointense and 1/3
was iso/hypointense.
dUHCA lesions were isointense on T1-WI before contrast enhancement. On T2-WI, 12/12 were isointense. On T1-WI after c.a., 2/12 lesions were isointense, 1/12
was hyperintense, 2/12 were hypointense with peripheral rim of contrast enhancement and 7/12 were hypointense.
SAA, anti-serum amyloid A2; GS, glutamine synthetase.
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function and contrast uptake. We used Gd-BOPTA, which, in the
clinical practice, has high relaxivity values (Shellock et al., 2006)
but only 5% of biliary excretion at 1-2 h after administration. The
use of Gd-BOPTA in mice has two main advantages: hepatobiliary
phase is already present ∼10 min after contrast administration,
and hepatobiliary excretion is ∼50%, because of a different
pharmacokinetic profile, as previously demonstrated (Lorusso
et al., 1999).
The detection of small HCC is challenging in the clinical practice.
In fact, the detection rate of human HCC <1 cm in diameter is only
34% (Lauenstein et al., 2007). Our protocol allows the visualization
and monitoring of small HCC/HCA nodules with a diameter of
1 mm and represents an important improvement in imaging
technique of murine liver nodules, compared with a study
reporting some difficulty in detecting lesions ≤2 mm (Freimuth
et al., 2010). The major advantage of our protocol is the possibility
to detect high-risk adenoma subtypes. In fact, by combining
information on all sequences, and especially contrast-enhanced T1-
WI, we were able not only to detect very small size lesions but also
to characterize and differentiate them into different histological
HCA subtypes.
UHCA remains the less-characterized adenoma subtype, with no
specific genetic/pathologic abnormalities and no specific MRI
pattern. In fact, UHCA showed all four different contrast
enhancement patterns and the majority were isointense on T2-WI.
During the follow-up study, we noticed that UHCA showing an
MRI pattern typical of IHCA had a slow growth rate, whereas
UHCA with evolving features and with an MRI pattern typical of
bHCA displayed a high growth rate. Bioulac-Sage and collaborators
reported that β-catenin activation was not detected in all nodules of
the same patient with adenomatosis, and suggested that β-catenin
mutation could occur later during adenoma carcinogenesis,
promoting malignant transformation (Bioulac-Sage et al., 2007).
Further studies will be required to better understand oncogenesis,
and to identify possible differences in clinical features and
pathologic and radiologic characteristics of this heterogeneous
HCA subtype. In this respect, due to the rarity of UHCA, preclinical
models can be useful tools to improve our knowledge in this field.
Nevertheless, our results suggest that some UHCA lesions could be
considered as the precursors of bHCA at an early stage of
carcinogenesis. We did not assess the correlation between tumor
markers and high-risk adenomas because tumor markers are most
useful for monitoring response to therapy and detecting early
relapse. In fact, with the exception of prostate-specific antigen
(PSA), tumor markers do not have sufficient sensitivity or
specificity for use in screening. Moreover, when proliferating
index biomarkers are analyzed, contradictory results are frequently
reached, leading to incorrect diagnosis (Rodríguez-Enríquez et al.,
2011). Nevertheless, a future study aimed at correlating information
on high-risk tumor obtained with MRI analysis and tumor markers
may be important to establish an efficient and reliable method to
differentiate between high-risk versus low-risk adenomas.
We show here that bHCA lesions display MRI features
distinguishable from those exhibited by IHCA or UHCA lesions,
indicating that our protocol is a reliable method for the identification
of high-risk HCA. This is an important achievement because GSD1a
patients often develop multiple adenomas that may originate from
independent clones and therefore have different molecular subtypes.
BecauseHCA is a rare disease, the information in the literature to help
guide treatment is low. The possibility of characterizing the different
HCA subtypes in patients with multiple adenomas is important for
planning surveillance and treatment.
In conclusion, this is the first study to report the possibility of
differentiating the various subtypes of hepatic adenoma using MRI
imaging. In this respect, the establishment of an optimized MRI
protocol to detect and analyze liver lesions in our mouse model for
GSD1a opens the possibility of applying such a protocol to patients
for non-invasive diagnostic purposes. A very recent study utilized a
similar MRI protocol to screen for HCC in patients with cirrhosis
or chronic hepatitis B. Reported results indicate that MRI
Fig. 4. Growth characteristics of IHCA. Tumor
measurement in LS-G6pc−/− mice was
performed on the basis of T1-weighted contrast-
enhanced scans. (A) A hyperintense lesion was
detected on T1-WI after c.a. at the first MRI
evaluation. (B) One month later, the lesion had
not changed in size and was classified as IHCA
by immunohistochemistry.
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characteristics similar to ours are suggestive of malignant
transformation (Tillman et al., 2018). We hope that our findings
can be translated to the human setting and therefore constitute the
basis for the development of an appropriate screening protocol for
GSD1a patients.
MATERIALS AND METHODS
Housing and breeding of mice
Male and female LS-G6pc−/−mice (Resaz et al., 2014), aged 13-18 months,
were included in the study. All animals were maintained in a conventional
animal facility in 12-h light/dark cycles, fed ad libitum and monitored for
their lifespan. All animal studies were reviewed and approved by the Ethical
Committee for Animal Experimentation (CSEA) as Animal Use Project No.
291, communicated to the Italian Ministry of Health with regard to the
article of the D.lgs 116/92, and carried out at the animal facility of the
National Institute for Cancer Research (Genova, Italy).
MRI analysis
MRI was performed with a clinical 3T MR system (Signa EXCITE®HDxT,
GE Healthcare, Milwaukee, WI, USA). Qualitative and quantitative
analyses were performed on a commercially available workstation (AW
Volume Share 2, ADW 4.4, GE Healthcare, Milan, Italy).
Mice were anesthetized by intraperitoneal injection of xylazine (30 mg/
kg) and ketamine (100 mg/kg) and positioned in a prototype coil (birdcage
linear coil, transmit/receive coil, 100 mm long, 55 mm diameter, tuned at
127.6 MH, Flick Engineering Solutions BV&Baio G&GE Milwaukee, WI,
USA), placed on a support filled with warm water to preserve mice from
hypothermia. For contrast enhancement, 0.05 mmol/kg body weight Gd-
BOPTA (MultiHance®) was administered by tail vein injection. The room
temperature during experiments was 23°C, and the mean acquisition time
was limited to 35 min by the spontaneous awakening of mice.
A short localizer sequence was performed and the field of view (FOV)
was centered on the upper abdomen. Based on these images, coronal before
and after contrast administration, T1-weighted and T2-weighted scans were
planned and acquired with parameters in chronological order, as shown in
Table 4. Each pre- and post-contrast sequence lasted ∼7 min. The
acquisition of all scans lasted ∼25 min. To obtain an HBP, the T1-WI
sequences were acquired ∼10 min after contrast administration.
A total of 40 animals aged 13-18 months were scanned by MRI and
checked for focal lesions in all sequences acquired. Twenty-five mice were
scanned once and sacrificed after the MRI session. The remaining 15 mice
were monitored every 4 weeks for 3 months to evaluate lesion growth and
complication onset, such as rupture and bleeding (see Table 2).
We performed both quantitative and qualitative analyses. We applied a
qualitative analysis using a five-point scale to T1-WI and T2-WI; the reader
assessed the signal intensity (SI) of the representative liver lesion relative to
the adjacent liver parenchyma: 1, very hypointense; 2, mildly hypointense;
3, isointense; 4, mildly hyperintense; and 5, very hyperintense (as biliary
cysts) (Ngu et al., 2016). We defined hypointense lesions as those that were
Fig. 5. Time-dependent monitoring of
hepatic lesions. (A-F) LS-G6pc−/−micewere
monitored every 4 weeks for 3 months, and
the tumor growth was analyzed by measuring
lesion diameter using the off-line workstation.
At the first MRI evaluation (A,B), one mouse
showed two lesions that were both
hypointense on contrast-enhanced T1-WI but
that showed different signals on T2-WI
imaging: the small nodule was hypointense
(arrows), whereas the bigger nodule was
hyperintense (dashed line arrows). After
1 month (C,D), one lesion (arrows) had
slightly changed in size and had become
hyperintense on T2-WI, while the other lesion
(dashed line arrows) had rapidly increased in
size and presented with a large central cystic
portion that can denote a necrosis area (bright
signal intensity). At the third MRI evaluation
(E,F), the small lesion (arrows) showed a size
increase of 50%, suggesting a high growth
rate, while the other lesion (dashed line
arrows) had not changed in size. Both lesions
were hypointense on T1-WI after c.a. and
hyperintense on T2-WI. They were classified
by immunohistochemistry as UHCA. A third
lesion, hyperintense on contrast-enhanced
T1-WI (arrowhead) and isointense on T2-WI,
was detected and identified as an IHCA.
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unequivocally darker than surrounding parenchyma, hyperintense lesions as
those that were unequivocally brighter than surrounding parenchyma and
isointense lesions as those that were not distinguishable from surrounding
parenchyma.
Quantitative analysis was expressed as relative signal intensity ratio
(RelSI) for each lesion, calculated both on T1-WI after contrast and on
T2-WI. Lesion and liver SI was measured using an operator-defined region
of interest (ROI). After defining the ROIs, we calculated the RelSI according
to the formula: RelSI=SI lesion/SI liver.
On T1-WI after contrast, we considered hypointense lesions as those that
were with a RelSI ≤0.8 and hyperintense lesions as those that were with a
RelSI ≥1.2. As isointense lesions were not distinguishable from the
surrounding parenchyma, they were not measurable (Table 1). Mildly
hyperintense lesions on T2-WI had a RelSI between 1.4 and 3.3,
unequivocally distinguishable from very hyperintense lesions (like cysts)
that showed a RelSI of 12-13.
Imaging acquired after contrast administration allowed the clear detection
of hepatic lesions and the distinguishing of four different patterns of contrast
uptake: isointense, very hyperintense and very hypointense lesions, and
lesions with a peripheral contrast enhancement (Fig. 3A-E).
These experiments demonstrated that the optimized parameters shown in
Table 4 allow precise/high spatial resolution MRI of small murine liver
tumors. In fact, 18 of 40 animals (45%) showed development of focal lesions,
ranging between 1 mm and 10 mm in diameter, with different combinations
of MRI characteristics and mainly detectable on contrast-enhanced T1-WI.
We observed a total number of 41 liver lesions (Tables 1 and 3).
Histology and immunohistochemistry
Mice were sacrificed shortly after the last MRI acquisition. All livers were
macroscopically analyzed for focal hepatic nodules. Before liver sampling,
the orientation of all liver lobes, relative to the longitudinal, transversal and
sagittal axis of the animal, was marked, and the size and location of the
macroscopic tumor nodes were measured with a caliper and correlated with
the MRI findings. Part of the respective liver was then embedded in paraffin
and used for diagnostic procedures. The rest of the liver was frozen for
further analysis.
All tissue samples were fixed in 10% buffered formalin for 24 h and
paraffin embedded. For histological analysis, 4-μm-thick serial sections
were stained with Hematoxylin and Eosin. Reticulin was visualized by
Gomori staining. Immunostaining was performed with anti-GS (Zulehner
et al., 2010) (1:500; ab49873, Abcam, Cambridge, UK) and anti-SAA
(1:100; PAB795Mu01, Cloud-Clone, Houston, TX, USA) antibodies.
Reactions were developed using an EnVision+ System-HRP (DAB)
(DAKO, Carpinteria, CA, USA). After immunostaining, slides were
counterstained with Hematoxylin. Positive and negative controls were
included for each run.
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